These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 16913396)

  • 21. Special patent provisions for pharmaceuticals: have they outlived their usefulness? A political, legislative and legal history of U.S. law and observations for the future.
    Engelberg AB
    Spec Law Dig Health Care Law; 2000 Sep; (258):9-48. PubMed ID: 11184791
    [No Abstract]   [Full Text] [Related]  

  • 22. Past, present and future of pharmaceutical patents under Korea-US Trade Agreement.
    Shin YS
    Pharm Pat Anal; 2016 Jul; 5(4):237-48. PubMed ID: 27338849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development.
    Matthews JH
    Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Innovation strategies for generic drug companies: moving into supergenerics.
    Ross MS
    IDrugs; 2010 Apr; 13(4):243-7. PubMed ID: 20373253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An industry update: the latest developments in therapeutic delivery.
    Simpson I
    Ther Deliv; 2018 Jan; 9(1):9-15. PubMed ID: 29216806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Follow-on biologics: data exclusivity and the balance between innovation and competition.
    Grabowski H
    Nat Rev Drug Discov; 2008 Jun; 7(6):479-88. PubMed ID: 18469828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intellectual property rights and the Canadian pharmaceutical marketplace: where do we go from here?
    Lexchin J
    Int J Health Serv; 2005; 35(2):237-56. PubMed ID: 15932005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intellectual property. Fixing the legal framework for pharmaceutical research.
    Knowles SM
    Science; 2010 Feb; 327(5969):1083-4. PubMed ID: 20150445
    [No Abstract]   [Full Text] [Related]  

  • 30. [Early achievements of the Danish pharmaceutical industry-7].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2014; (42):31-62. PubMed ID: 25816561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Excavating treasure from the amber of the prior art: why the public benefit doctrine is ill-suited to the pharmaceutical sciences.
    Hess RA
    Food Drug Law J; 2011; 66(1):105-20, iii. PubMed ID: 24505849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patent indicators: a window to pharmaceutical market success.
    Guo Y; Hu Y; Zheng M; Wang Y
    Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
    Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measuring the efficiency of large pharmaceutical companies: an industry analysis.
    Gascón F; Lozano J; Ponte B; de la Fuente D
    Eur J Health Econ; 2017 Jun; 18(5):587-608. PubMed ID: 27344446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective.
    Germann PG; Schuhmacher A; Harrison J; Law R; Haug K; Wong G
    Hum Genomics; 2013 Mar; 7(1):5. PubMed ID: 23496921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are prescription drug prices high?
    Vagelos PR
    Science; 1991 May; 252(5009):1080-4. PubMed ID: 2031182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics Of Key Patents Covering Recent FDA-Approved Drugs.
    Van de Wiele VL; Torrance AW; Kesselheim AS
    Health Aff (Millwood); 2022 Aug; 41(8):1117-1124. PubMed ID: 35914209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation and Innovation: Role of Regulatory Science in Facilitating Pharmaceutical Innovation.
    Honig P; Zhang L
    Clin Pharmacol Ther; 2019 Apr; 105(4):778-781. PubMed ID: 30883715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation.
    Malhotra H
    Biologicals; 2011 Sep; 39(5):321-4. PubMed ID: 21784652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.